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ABSTRACT 
Human serum albumin (HSA) has seven common fatty acid (FA) binding sites. In this study, 
we used MM-PBSA method to identify high affinity FA binding sites on HSA in terms of 
binding free energy. Using multiple HSA-FA (myristate, palmitate) complex models 
constructed by molecular dynamics simulations, two methods were performed in MM-PBSA, 
the “three trajectory method” and the “single trajectory method”. The former, which is less 
precise than the latter but may be more accurate as it includes the effects of conformational 
change upon binding, was used to classify high and low affinity sites. As a result, Sites 2, 4, 
and 5 were identified as high affinity sites for both FAs. The latter method, which is precise 
because energies are calculated from snapshots of the same trajectory for HSA-FA complex, 
was performed to compare the magnitude of binding free energy for these sites. The order of 
magnitude was 5 > 4 > 2; identical to that of a previous publication by Simard et al..  In this 
way, a combination of the two methods was effectively used to identify high affinity sites. 
The present study therefore provides an insight into the quantitative identification of high 
affinity FA binding sites on HSA. 
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INTRODUCTION 
Human serum albumin (HSA) is a major protein component of blood plasma. It serves 
as a transport protein for several endogenous compounds, such as unesterified fatty acids 
(FA) and bilirubin, and is also capable of binding a broad spectrum of therapeutic agents.  
Drug binding to HSA can result in a prolonged in vivo half-life. Thus, the binding property of 
drugs to HSA is one of the most important factors determining their pharmacokinetics (1). 
HSA consists of 585 amino acids and has a molecular mass of 66500 Da. Recently, 
three dimensional structures of HSA have been obtained by X-ray crystallography (2-4). The 
structure of HSA consists of three homologous domains (domains I-III), each of which is 
divided into two subdomains, A and B, having six and four α-helices, respectively. For these 
subdomains, the positions and architecture of a broad spectrum of drugs have been identified 
by X-ray crystallography of HSA-drug complexes (5). The positions and architecture of FA 
binding sites on HSA have been also identified for these subdomains (6-9). Seven common 
FA binding sites have been identified for medium and long-chain FAs (8), and monosaturated 
and polyunsaturated FAs (9). 
 Under normal physiological conditions, HSA binds with approximately 0.1–2 moles 
of FA, per mol of protein (10). However, the molar ratio of FA/HSA can rise up to 6 during 
fasting or maximum exercise, resulting from an increase in FA in blood plasma (11,12). Drug 
binding to HSA can be modulated by simultaneous binding of FAs (1,5,13), therefore it is 
important to clarify the binding affinity of FA at each FA binding site on HSA. Very recently, 
the locations of high affinity FA binding sites on HSA have been reported (14-16). Simard et 
al. showed three high and four low affinity FA binding sites of palmitate (PLM) on HSA by 
combining 13C NMR spectroscopy with drug-competition analysis (15). Kragh-Hansen et al. 
investigated high affinity binding sites of octanoate, decanoate, laurate, and myristate (MYR) 
by site-directed mutagenesis of HSA (16). Although these works give an insight into the 
binding of FA to HSA, they do not compare the absolute binding affinity of each FA binding 
site. 
 Several theoretical methods have recently been developed to estimate the binding free 
energy between protein and ligand, such as free energy perturbation (FEP) (17), the linear 
interaction energy (LIE) method (18) and the molecular mechanics Poisson-Boltzmann 
surface area (MM-PBSA) method (19). Of these methods, MM-PBSA is promising because it 
requires less computer resources than FEP and, contrary to LIE, applies no empirical 
parameters in its free energy calculations. In MM-PBSA, the binding free energy of a given 
protein-ligand complex is calculated by summing up molecular mechanical energies, 
solvation energies, and entropic terms. In addition, by performing molecular dynamics (MD) 
simulation of the given protein-ligand complex, the ensemble averages of these properties are 
obtained. MM-PBSA method has been successfully applied to several “multiple ligands 
bound to one binding site” systems (20-25). As far as we know, however, there are no 
published works that apply the MM-PBSA method to a “one ligand bound to multiple 
binding sites” system. 
 The present study was undertaken to quantitatively elucidate high and low affinity FA 
binding sites on HSA by MM-PBSA calculations. This is the first report that has applied 
MM-PBSA to a “one ligand (FA) bound to multiple binding sites (on HSA)” system. We 
focused on the binding of PLM, one of the most common FAs transported by HSA in plasma 
(26), and MYR, commonly used for examining the effect of FA on HSA (5,13). In this article, 
we present the calculated binding free energy results of two methods, termed the “three 
trajectory method” and the “single trajectory method”. The former is used to classify high 
and low affinity FA binding sites, and the latter to compare the magnitude of binding free 
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energy among high affinity sites identified by the former. Based on the MM-PBSA results, 
we compare the calculated binding free energy with the experimental multiple binding 
constants (27-29). In addition, we show that conformational changes in HSA by the binding 
of one FA molecule differed according to the binding site.  
 
MATERIALS AND METHODS 
Starting structure of HSA-fatty acid complex 
 The initial coordinates of HSA-FA complex were obtained from the Protein Data 
Bank (PDB) (30) (HSA-PLM complex: 1E7H, HSA-MYR complex: 1E7G, the resolutions of 
the structures were 2.4 and 2.5 Å, respectively). In PDB entry 1E7H (8), seven PLM 
molecules were bound to HSA, and all were included in the following MD simulations 
(HSA-7PLM complex). On the other hand, eight MYR molecules were bound to HSA in 
PDB entry 1E7G (8). In this study, MYR bound to Site 2´ was removed because seven 
molecules were bound to the sites, in common with all medium and long chain FAs (8,9). 
Hence, seven MYR molecules were included in the following MD simulations (HSA-7MYR 
complex; Figure 1).  
 
Molecular dynamics simulations of HSA-fatty acid complex 
 A series of MD calculations were carried out using the AMBER8 package (31). The 
LEaP module was used for model construction of HSA-FA complex. The sander module was 
used for energy minimization, and the pmemd module was used for MD calculations. The 
AMBER (parm94) force field (32) was used for modeling the HSA system. PLM and MYR 
force fields were generated by the antechamber module, based on the general AMBER force 
field (GAFF) (33). Following ab initio optimization of FA molecule at the HF/6-31G* level 
by Gaussian 03 (34), a restrained electrostatic potential fit procedure (35) was used as the 
charge method in GAFF. Missing residues in the starting structure of HSA (residues 1, 2, 584, 
585) were added by the Build and Edit Protein tool on Discovery Studio (version 1.5) (36). 
Following the addition of missing residues, missing atoms were added by the LEaP module. 
Energy minimization with constraints on the positions of heavy atoms was carried out for 500 
steps. Na+ counterions were placed by LEaP to neutralize the negative charges of both HSA-
FA complex models at pH 7. A rectangular-shaped box of water was constructed using the 
TIP3P water model (37), with the buffering distance set to 12 Å. The resulting model systems 
contained 97447 (HSA-7PLM complex) and 98473 (HSA-7MYR complex) atoms. The 
single FA molecule system was also constructed according to the same criterion, and the 
model systems contained 3662 (PLM molecule) and 3440 (MYR molecule) atoms. For each 
system, 500 steps of energy minimization constraining the HSA and/or FA molecules were 
carried out, followed by 500 steps of energy minimization with no constraints. After energy 
minimization, 8 ns MD calculations were carried out for each HSA-seven FA complex model 
(HSA-7FA) under periodic boundary conditions. The nonbonded list was generated using an 
atom-based cutoff of 8 Å. The long-range electrostatic interactions were handled by the 
particle-mesh Ewald algorithm (38). The time step of the MD simulations was set to 2.0 fs, 
and the SHAKE algorithm (39) was used to constrain bond lengths at their equilibrium values. 
Temperature and pressure were maintained using the weak-coupling algorithm (40) with 
coupling constants τT and τP of 1.0 ps and 0.2 ps, respectively (310 K, 1 atm). Coordinates 
were saved for analyses every 1 ps.   
 Seven HSA-one FA complex models (HSA-1FAs) and the unliganded HSA model 
were obtained by removing six or seven other FA molecules from the snapshot of HSA-7FA 
complex at 4 ns, with the velocity of each atom unchanged from that at 4 ns, to prevent from 
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sampling different conformational space between the HSA models. Starting with seven HSA-
1FA complex models and one unliganded HSA model, additional 4 ns MD simulations were 
performed for each model under the same conditions as above. 
 The MD simulations and subsequent MM-PBSA calculations were run on an in-house 
PC cluster composed of 8 nodes (AMD Opteron 2.2 GHz, 2 GB DDR memory) with a gigabit 
ethernet interconnection. 
 
MM-PBSA calculations for binding free energy 
 Binding free energy (ΔGbind) of FA at each FA binding site on HSA was calculated as 
follows: 
complex HSA FA
bindG G G GΔ = − −    (1) 
where Gcomplex, GHSA, and GFA are the free energies of complex, HSA, and FA, respectively. 
Free energy (G) of each state was calculated as follows: 
MM PB SAG E G G TS= + + −    (2) 
MM vdw ele intE E E E= + +    (3) 
where EMM is the molecular mechanical energy, GPB and GSA are the contributions from polar 
and nonpolar terms of the free energy of the solvent continuum, and TS is the entropic 
contribution of the solute. EMM was obtained by summing contributions from internal energies 
including bond, angle, and torsional angle energies (Eint), electrostatic energy (Eele), and van 
der Waals energy (Evdw), using the same force field as that of MD simulations with no cutoff. 
GPB was calculated using the DELPHI program (41) with PARSE (42) atom radii and 
standard AMBER94 charges (32) for amino acids. The dielectric constants inside and outside 
the molecule were 1.0 and 80.0, respectively. GSA was calculated using a solvent accessible 
surface area (SASA) as follows: 
SAG SASA bγ= × +     (4) 
The SASA was computed with the molsurf module in AMBER8 (31), using a probe radius of 
1.4 Å. The surface tension proportionality constant (γ) and the free energy of nonpolar 
solvation for a point solute (b) were set to 0.00542 kcal/mol/Å2 and 0.92 kcal/mol, 
respectively (42). Estimates of conformational entropies were computed with the nmode 
module in AMBER8 (30). Entropic contributions from translational and rotational motion 
were taken from classical statistical thermodynamics (43), and entropic contribution from 
vibrational motion was obtained by normal mode analysis (44). Following energy 
minimization of the snapshot with a distance-dependent dielectric function (ε = 4Rij) until the 
root mean square of the elements of the gradient vector was less than 10−4 kcal/mol/Å, 
frequencies of the vibrational modes were computed at 300 K for the minimized structures 
using a harmonic approximation of the energies. 
 For the binding free energy calculations by MM-PBSA, 500 snapshots of each model 
were taken at time intervals of 6 ps from the 3 ns production runs (5-8 ns). However, entropic 
contributions were evaluated for only 20 snapshots taken at time intervals of 150 ps from the 
3 ns production runs, because of the rather large computational expense. In addition, only 
subdomains of HSA that participated in the binding of FA were used for calculating the 
entropic contribution (Site 1: IB; Site 2: IA, IB, IIA; Site 3: IIB, IIIA; Site 4: IIIA; Site 5: 
IIIB; Site 6: IIA, IIB; Site 7: IB, IIA). 
 
”Three trajectory method” and “single trajectory method” 
 In the present MM-PBSA calculations, two trajectory set methods were performed. 
The “three trajectory method” used snapshots extracted from three trajectories of complex, 
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FA, and unliganded HSA and the “single trajectory method” used snapshots extracted from a 
single trajectory of the HSA-FA complex. The binding free energy of the three trajectory 
method was calculated as follows: 
complex HSA FA
bindG G G GΔ = − −   (5) 
where " denotes an average of snapshots taken from MD trajectories. The binding free 
energy was calculated for the single trajectory method, as follows: 
complex HSA FA
bindG G G GΔ = − −   (6) 
It should be noted that the change in internal energies (ΔEint) equals zero in calculating the 
binding free energy according to Eq. 6, since the internal energies of the complex and the 
separated parts are calculated from the same trajectory. 
 
RESULTS AND DISCUSSION 
Root mean square deviation of HSA-fatty acid complex and unliganded HSA 
 The root mean square deviation (RMSD) of Cα atoms from the X-ray structure in 
HSA-FA complex systems are shown in Figure 2. In each system, RMSD values reached 
plateau at about 2 ns (see Figure 2A). Calculated from the 4- to 8-ns trajectory data, the 
RMSD values of Cα atoms in the whole HSA molecules were 2.58 ± 0.23 Å and 3.03 ± 0.23 
Å for HSA-7MYR complex and HSA-7PLM complex, respectively. We also calculated the 
RMSD of Cα atoms in each subdomain to analyze which region of HSA undergoes large 
conformational changes (Figure 3). In both HSA-7FA models, subdomains IA and IIIB 
showed larger RMSD values, suggesting that larger conformational changes occur at these 
subdomains. Some of the recent MD studies, which were carried out under similar conditions 
with the present MD simulations, reported that the RMSD values reached between 2 and 4 Å 
(45,46). Taking into account of the relatively low resolution of the crystal structures of HSA 
(2.4-2.5 Å), we conclude that no significant structural drift from the X-ray structure occurred 
during the MD simulations. 
 Additional 4 ns MD of unliganded HSA models also showed that no significant 
structural drift occurred during the MD simulations and that RMSD values reached plateau at 
about 5 ns in both systems (Figure 2B). For the HSA-1FA complex models, RMSD also 
reached plateau at about 5 ns (see the Supplementary Material). In comparisons of the 
unliganded HSA models with the crystal structure of unliganded HSA (PDB entry 1AO6), 
RMSD values of Cα atoms in the whole HSA molecule were 3.40 ± 0.20 Å (from HSA-
7PLM complex) and 5.07 ± 0.40 Å (from HSA-7MYR complex), calculated from 5-8 ns 
trajectory. Although the RMSD value from the crystal structure was large in unliganded HSA 
model constructed from HSA-7MYR complex, the RMSD value in each FA binding site (Site 
1-7) was between 2 and 4 Å, suggesting that no significant structural drift from the crystal 
structure occurred in each FA binding site on HSA. Therefore, the deviations from the crystal 
structure observed as above may not affect significantly the binding free energy calculation 
by the three trajectory method. In the present study, we used 5-8 ns trajectories in the 
following MM-PBSA calculations. 
 
Two types of MM-PBSA for identifying high affinity FA sites 
 The single trajectory method (Eq. 6) has been used in many MM-PBSA studies owing 
to the considerable reduction in computer time due to MD simulation for only one complex 
model (20,21,25,47). On the basis that large conformational changes do not occur upon 
binding, the single trajectory approach has the benefit of error cancellation in internal 
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energies (ΔEint) and high correlation between variations of Gcomplex and (GHSA + GFA), resulting 
in precise estimation of the binding free energy. In the present study, however, 
conformational changes of HSA by the binding of FAs have been reported (6,48), and the 
contribution of each FA binding site to the conformational changes upon FA binding may be 
different. Therefore, the single trajectory method, which can not include the effect of 
conformational changes on HSA by the binding of FA, may not be appropriate for ranking the 
binding free energies among FA binding sites with conformational changes. 
 On the other hand, the three trajectory method (Eq. 5) does have value in that it may 
calculate total free energy change, including intramolecular strain, characterized as ΔEint, and 
an induced fit effect, by the binding of FA on HSA. In fact, some papers reported the 
significant effect of including ΔEint in the binding free energy (47,49). However, the three 
trajectory method is less precise compared to the single trajectory method, because it includes 
an additional source for errors, the contribution of internal energy term (ΔEint), and does not 
include cancellation of errors derived from correlation between variations of Gcomplex and 
(GHSA + GFA) (23,47). Because of the additional errors, the three trajectory method may not be 
appropriate for ranking the binding free energy of each FA binding site, especially with 
similar binding conformations. 
 In the present study, based on the characteristics of the two types of MM-PBSA as 
mentioned above, we used the two methods in a following way; in comparisons between FA 
binding sites where large conformational changes can occur upon binding, the three trajectory 
method may be more accurate for calculation of binding free energy, than the single trajectory 
method. Furthermore, contributions from each energy component in HSA-FA interactions are 
assumed to be quite different between high affinity and low affinity sites. Taking these points 
into account, we first used the three trajectory method to classify high and low affinity FA 
binding sites on HSA. In addition, even if conformational changes occur upon FA binding, it 
can be expected that, at favorable FA binding sites, a given FA molecule binds to each site in 
a similar way. Thus the binding energies can be compared between the sites, although some 
bias, which is in common with all the sites, may be involved in the estimation. Based on this 
assumption, we next used the single trajectory method to compare the magnitude of binding 
free energy between high FA binding sites.  
 
MM-PBSA for binding of palmitate on HSA 
 Table I shows the calculated binding free energy components of HSA-1PLM complex 
based on the three trajectory method. The binding free energy (ΔGbind) indicated large 
positive values at Sites 6 and 7. In the first published work regarding X-ray crystallographic 
analysis of HSA-MYR complex, only Sites 1–5 were detected using a lower FA to protein 
molar ratio (6), suggesting that Sites 6 and 7 are low affinity FA binding sites. The results of 
the present study were consistent with those of previous work. In addition, the binding free 
energy indicated large positive values at Site 3 (18.0 kcal/mol), which is also in accordance 
with previous work reporting that the binding of PLM at Site 3 is weak (15). Consequently, 
we identified Sites 3, 6, and 7 as low affinity PLM binding sites. Simard et al. (15) reported 
that three high (Sites 2, 4, and 5) and four low PLM binding sites (Sites 1, 3, 6, and 7) exist 
on HSA. In the present study, the magnitude of the binding free energy at Site 1 (although a 
negative value was indicated) was much smaller than that of Sites 2, 4, and 5 (Table I), 
suggesting that the binding affinity at Site 1 is weaker than that of the other three sites.   
 Table II shows the calculated binding free energy components of HSA-1PLM 
complex using the single trajectory method. Focused on high affinity binding sites identified 
by the three trajectory method (Sites 2, 4, and 5), the order of the binding free energy was 5 > 
 7
4 > 2. This result was in line with previous work by Simard et al. (15). Because the other 
PLM binding sites (Sites 1, 3, 6, 7) were already identified as low affinity sites by the three 
trajectory method, we did not include these binding sites in comparison of the binding free 
energy by the single trajectory method, although the binding free energy at Sites 1 and 3 
indicated relatively large negative values by the single trajectory method. If only the result of 
single trajectory method was used, the trend of binding affinity was 5 > 1 > 3 > 4 > 2 > 7 > 6, 
and Sites 1 and 3 might be misclassified as high affinity FA binding sites. 
 In summary, we identified Sites 2, 4, and 5 as high affinity PLM binding sites, where 
Site 5 was the highest affinity binding site. In addition, the present study indicated that a 
combination of the three trajectory and single trajectory methods are effective in MM-PBSA 
calculations for determining high and low affinity binding sites, and the order of affinity for 
the high affinity sites. 
 
MM-PBSA for binding of myristate on HSA 
 We performed MM-PBSA calculations for the binding of MYR on HSA. Table III 
shows the calculated binding free energy components of HSA-1MYR complex based on the 
three trajectory method. The binding free energy indicated large positive values at Sites 1, 3, 
6 and 7, suggesting that these sites are low affinity binding sites for MYR. At Sites 2, 4 and 5, 
the binding free energy showed near-zero or negative values, indicating that they are high 
affinity MYR binding sites on HSA. The present MM-PBSA result was a little inconsistent 
with previous experimental work by Kragh-Hansen et al. (16), which reports that Sites 1, 5, 
and 4 are high affinity MYR binding sites on HSA. However, the group did not check the 
binding affinity of MYR at Site 2, because they have not yet produced mutants for Site 2 (16). 
Considering that only a small difference in carbon chain length exists between PLM (C16) 
and MYR (C14), similar binding modes are expected between these FAs. It might be possible 
that Site 2 and not Site 1 is one of the high affinity FA binding sites for MYR.  
 We also calculated binding free energy components of HSA-1MYR complex using 
the single trajectory method (Table IV). Focusing on high affinity binding sites identified by 
the three trajectory method (Sites 2, 4, and 5), the order of the binding free energy was 5 > 4 
> 2, thus corresponding to the present MM-PBSA calculations for PLM. Combining the 
results of the single trajectory and three trajectory methods, we identified Sites 2, 4, and 5 as 
high affinity MYR binding sites, where Site 5 was the highest affinity binding site, as is the 
case with PLM. 
 
Difference in ranking of the binding free energy between two types of MM-PBSA 
 The order of the magnitude of binding free energy at each FA binding site using the 
single trajectory method did not coincide with that of the three trajectory method, particularly 
for MYR. The difference between the two methods defines whether or not intramolecular 
strain, characterized as ΔEint, and induced fit effects are included with the calculated binding 
free energy. The intramolecular strain, caused by the binding of FA on HSA, was different at 
each FA binding site, as shown in Tables I and III. Remarkable changes in strain were 
observed at Site 5 for PLM binding, and at Sites 2, 4, 5 for MYR binding. 
 In addition, we analyzed how much induced fit occurred by the binding of FA to each 
FA binding site on HSA. Table V shows RMSDs of Cα atoms of unliganded HSA and HSA-
1FA complex (5-8 ns) from unliganded HSA at 6 ns. RMSDs of each HSA-1FA complex 
binding site increased by FA binding, indicating that an induced fit effect occurred upon 
binding of FA to HSA. The extent of the increase in RMSD differed among FA binding sites, 
and more than 1 Å increase in RMSD was observed at Sites 1, 2, and 5 for PLM binding, and 
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Sites 1 and 5 for MYR binding. It is interesting to note that the sites indicating large 
fluctuation (RMSD of Cα atoms) were not necessarily large in ΔEint, such as Site 1. By 
contraries, a large deviation was not observed at Site 3. If intramolecular strain was 
considered in the single trajectory method (Table IV), the actual magnitude of the binding 
free energy of MYR might be larger at Sites 4 and 5 than at Site 3. This is because the 
intramolecular strain is more favorable at Sites 4 and 5, as shown in Table III. In addition, 
taking into account the large conformational change observed at Site 5 by the binding of 
MYR, it is possible that the conformational change leads to more favorable FA—and thus 
highest—binding at Site 5. Although these differences do not directly explain the difference 
in the order of magnitude of binding free energy between the two methods, it is implied that 
both intramolecular strain and induced fit were intricately interrelated and caused a marked 
effect on the binding free energy. 
 
Comparison of calculated binding free energy with experimental affinity data 
 How well do the binding free energies calculated by MM-PBSA calculations 
correspond to the experimental binding affinity constant? We compared the experimental 
affinity constants (27-29) with the calculated binding free energies of the single trajectory 
method. Figure 3 shows the relationship between experimental and calculated binding free 
energy for the three high affinity FA binding sites (Sites 2, 4, 5). Many of the calculated 
binding free energies deviated greatly from the experimental binding free energies, as shown 
in Figure 3. Furthermore, the calculated binding free energies of PLM were smaller than 
those of MYR. This result was inconsistent with previous reports showing that the magnitude 
of the affinity constant increased as the carbon chain length of the FA increased (16,27,29,50). 
It is reported that weak and strong binders that differ less than 2–3 orders of magnitude in 
IC50 (corresponding to ΔΔGbind ≤ 4.8 kcal/mol) are poorly distinguished by MM-PBSA (51), 
and the present comparison between PLM and MYR may be attributed to this. More rigorous 
approaches are required to accurately estimate the binding free energy of each ligand.  
 On the other hand, the binding free energies calculated by the three trajectory method 
(Tables 1, 3) were much more deviated from the experimental binding free energies. As 
mentioned above, one of the reasons may be that the three trajectory method is less precise 
than the single trajectory method. Furthermore, the free energies (Gmmpbsa) of the two 
unliganded HSA models constructed from the HSA-7FA models were quite different between 
each other (−19581.2 ± 93.7 kcal/mol and −17633.2 ± 80.5 kcal/mol from HSA-7PLM 
complex and HSA-7MYR complex, respectively), suggesting that only a limited 
conformational space was used for the binding free energy calculation by the three trajectory 
method. By sampling a full conformational space from each HSA and HSA-FA model, the 
calculated binding free energies may be more comparable with the experimental binding free 
energies; however, it is remarkably difficult to get an enough conformational space of HSA, 
as in our previous study, reporting that even 10 ns MD simulations did not get a full 
impression of the conformational freedom of HSA (48).  
 
Change in radius of gyration of HSA by binding of fatty acids 
 Under normal physiological conditions, HSA binds with approximately 0.1-2 moles of 
FA per mol of protein (10), and the molar ratio of FA/HSA can rise up to 6 during fasting or 
maximum exercise (11,12). Based on the present MD simulations, we analyzed 
conformational changes of unliganded HSA by the binding of FAs. Table VI summarizes the 
radius of gyration (Rg) of unliganded HSA and HSA-1FA complexes, obtained from the 5-8 
ns trajectory data from MD simulations. We modeled HSA under normal physiological 
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conditions as HSA-1FA complex in which FA is bound to Site 2, 4, or 5  (identified as high 
affinity FA binding sites), and during fasting or maximum exercise as HSA-7FA complex. 
The binding of seven FA molecules to HSA caused an increase in Rg of unliganded HSA, in 
line with previous studies (6,48). It is interesting that the binding of one FA molecule at Site 5 
also caused a remarkable increase in Rg. In the present study, Site 5 was identified as the 
highest binding affinity site, and it is suggested that induced fit caused the increase, as shown 
in Table V. Thus, it is supposed that the total volume of HSA under normal physiological 
conditions is larger than that of unliganded HSA.  
 
CONCLUSION 
 In the present study, high and low affinity FA binding sites on HSA were discussed 
quantitatively, based on the results of MM-PBSA calculations. According to the two 
trajectory set methods, three high affinity FA binding sites and the order of the magnitude of 
these three FA binding sites were identified for PLM and MYR. The radius of gyration of 
unliganded HSA increased remarkably by the binding of one FA molecule to the highest FA 
binding site, Site 5. Thus, the present study revealed high and low FA binding sites for PLM 
and MYR, and possible conformational changes of HSA by the binding of FAs. In addition, 
the present study illustrated the efficacy of combining the three trajectory and single 
trajectory methods. However, more rigorous approaches are required to accurately estimate 
the binding free energy. Nevertheless, the present MM-PBSA calculations agreed well with 
experimentally determined high and low FA binding sites. The present analysis can be 
applied to the other FAs bound to HSA, as well as other “one ligand bound to multiple 
binding sites” systems. In conclusion, the present study theoretically makes an important 
contribution to the identification of high affinity FA binding sites on HSA. 
 
Supplementary Material 
 RMSD values of the HSA-1PLM and HSA-1MYR complex models (4-8 ns). 
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Table I. Binding free energy components of HSA-1PLM complex in the three trajectory 
method (in units of kcal/mol).* 
 
 ΔEele ΔEvdw ΔEint ΔGSA ΔGPB ΔGmmpbsa† TΔS‡ ΔGbind¶
Site 1 166.7 −19.1 −2.9 −1.8 −175.8 −32.9 −20.5 −12.4 
 (9.8) (2.4) (4.4) (0.1) (9.1) (5.7) (1.5) (5.9) 
Site 2 131.1 12.0 −2.3 −2.6 −262.2 −124.0 −15.8 −108.1 
 (10.7) (2.6) (4.4) (0.2) (10.7) (5.5) (3.3) (6.4) 
Site 3 65.0 −24.2 4.6 −4.9 −43.2 −2.8 −20.8 18.0 
 (9.9) (2.4) (4.4) (0.1) (10.7) (5.6) (2.5) (6.2) 
Site 4 111.1 −21.3 0.9 −3.0 −151.4 −63.7 −17.9 −45.8 
 (9.6) (2.5) (4.4) (0.1) (9.7) (5.7) (1.9) (6.0) 
Site 5 16.5 0.7 −25.2 −0.7 −40.3 −49.0 −16.2 −32.8 
 (8.7) (2.5) (4.4) (0.1) (8.7) (5.3) (1.6) (5.5) 
Site 6 87.6 −14.5 −5.9 −3.6 −44.7 18.8 −23.7 42.4 
 (9.4) (2.5) (4.4) (0.1) (9.4) (5.6) (2.5) (6.2) 
Site 7 187.3 −44.1 −2.5 −6.1 −120.3 14.3 −19.6 33.8 
 (8.6) (2.4) (4.2) (0.1) (8.8) (5.2) (2.8) (5.9) 
 
*Number in parentheses is standard error of the mean. 
†
mmpbsa ele vdw int SA PBG G G G GΔ = Δ + Δ + Δ + Δ + ΔG . 
‡The absolute temperature (T) was set to 300 K in the MM-PBSA calculations. 
¶ΔGbind was calculated according to Eq. 5. 
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Table II. Binding free energy components of HSA-1PLM complex in the single trajectory 
method (in units of kcal/mol).*
 
 ΔEele ΔEvdw ΔGSA ΔGPB ΔGmmpbsa TΔS ΔGbind
Site 1 −10.5 −43.8 −5.7 27.9 −32.1 −21.0 −11.0 
 (0.2) (0.1) (0.007) (0.2) (0.2) (0.9) (0.9) 
Site 2 −4.4 −41.5 −6.0 23.7 −28.1 −20.0 −8.1 
 (0.2) (0.1) (0.008) (0.3) (0.2) (2.1) (2.2) 
Site 3 −12.9 −44.5 −5.5 34.1 −28.8 −19.6 −9.2 
 (0.1) (0.1) (0.008) (0.2) (0.2) (1.4) (1.4) 
Site 4 −13.2 −45.7 −5.8 35.7 −28.9 −20.0 −8.9 
 (0.2) (0.1) (0.004) (0.2) (0.2) (1.5) (1.5) 
Site 5 −23.2 −46.4 −5.6 45.0 −30.2 −18.1 −12.0 
 (0.4) (0.1) (0.006) (0.3) (0.2) (1.1) (1.1) 
Site 6 −6.4 −44.8 −5.6 29.8 −27.0 −23.4 −3.6 
 (0.2) (0.1) (0.005) (0.2) (0.2) (1.7) (1.7) 
Site 7 −16.1 −40.5 −5.6 38.2 −24.1 −17.6 −6.4 
 (0.2) (0.1) (0.010) (0.2) (0.2) (1.5) (1.5) 
 
*See footnotes of Table I; however, ΔGbind was calculated according to Eq. 6. 
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Table III. Binding free energy components of HSA-1MYR complex in the three trajectory 
method (in units of kcal/mol).*
 
 ΔEele ΔEvdw ΔEint ΔGSA ΔGPB ΔGmmpbsa TΔS ΔGbind
Site 1 225.9 −26.4 −1.5 −4.2 −172.0 21.8 −16.2 38.0 
 (12.0) (2.6) (4.5) (0.2) (11.1) (5.1) (1.5) (5.3) 
Site 2 77.5 −28.0 18.1 −4.2 −115.9 −52.5 −15.1 −37.4 
 (11.8) (2.6) (4.6) (0.1) (10.3) (5.5) (3.1) (6.3) 
Site 3 339.6 −40.6 −6.6 −3.4 −268.3 20.7 −19.7 40.4 
 (11.1) (2.5) (4.6) (0.1) (10.2) (5.0) (2.2) (5.5) 
Site 4 406.3 −22.5 −22.5 −0.8 −375.0 −8.0 −14.0 6.0 
 (11.1) (2.4) (4.5) (0.1) (10.4) (5.0) (1.9) (5.3) 
Site 5 440.6 13.9 −11.7 1.6 −458.7 −14.2 −21.4 7.2 
 (11.5) (2.8) (4.5) (0.1) (10.8) (5.1) (1.6) (5.3) 
Site 6 316.7 −22.7 −2.1 −2.9 −283.6 5.4 −19.6 25.0 
 (12.0) (2.6) (4.5) (0.1) (11.0) (5.0) (2.0) (5.4) 
Site 7 204.0 −1.0 −2.3 −3.2 −194.0 8.1 −21.5 29.7 
 (12.3) (2.6) (4.5) (0.1) (11.1) (5.2) (1.4) (5.4) 
 
*See footnotes of Table I. 
 16
Table IV. Binding free energy components of HSA-1MYR complex in the single trajectory 
method (in units of kcal/mol).* 
 
 ΔEele ΔEvdw ΔGSA ΔGPB ΔGmmpbsa TΔS ΔGbind
Site 1 −3.0 −37.6 −5.3 17.2 −28.8 −18.3 −10.5 
 (0.1) (0.2) (0.01) (0.2) (0.2) (1.0) (1.0) 
Site 2 −7.9 −39.2 −5.5 27.0 −25.5 −22.0 −3.6 
 (0.2) (0.1) (0.004) (0.2) (0.2) (2.4) (2.4) 
Site 3 −34.9 −37.5 −5.2 42.5 −35.1 −20.2 −15.0 
 (0.3) (0.2) (0.01) (0.2) (0.2) (1.4) (1.4) 
Site 4 −6.4 −36.9 −5.3 18.3 −30.3 −18.7 −11.7 
 (0.3) (0.1) (0.006) (0.2) (0.2) (1.8) (1.9) 
Site 5 −10.6 −41.5 −5.2 24.0 −33.3 −18.4 −14.9 
 (0.2) (0.1) (0.006) (0.2) (0.2) (1.1) (1.1) 
Site 6 −4.2 −39.4 −5.2 21.8 −27.0 −21.4 −5.6 
 (0.1) (0.1) (0.005) (0.2) (0.2) (1.4) (1.4) 
Site 7 −11.0 −31.8 −5.1 25.8 −22.1 −18.1 −4.0 
 (0.4) (0.1) (0.007) (0.4) (0.2) (2.2) (2.2) 
 
*See footnotes of Table I; however, ΔGbind was calculated according to Eq. 6. 
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Table V. Root mean square deviation of each FA binding site of unliganded HSA and HSA-
1FA complex (5-8 ns) from unliganded HSA at 6 ns (in units of Å). 
 
 Palmitate Myristate 
 Unliganded Complex Unliganded Complex 
Site 1 (108–196) 1.26 ± 0.32 2.62 ± 0.20 1.06 ± 0.16 2.10 ± 0.16 
Site 2 (1–297) 1.75 ± 0.37 2.87 ± 0.18 1.38 ± 0.24 1.70 ± 0.22 
Site 3 (298–497) 1.19 ± 0.16 2.07 ± 0.31 1.33 ± 0.21 1.69 ± 0.15 
Site 4 (384–497) 0.91 ± 0.18 1.50 ± 0.10 1.02 ± 0.20 1.52 ± 0.10 
Site 5 (498–585) 1.07 ± 0.22 2.08 ± 0.17 1.27 ± 0.27 3.41 ± 0.37 
Site 6 (197–383) 1.19 ± 0.20 1.52 ± 0.15 1.30 ± 0.19 1.70 ± 0.16 
Site 7 (108–297) 1.29 ± 0.30 2.00 ± 0.17 1.38 ± 0.29 1.97 ± 0.25 
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Table VI.  Radius of gyration of unliganded HSA and HSA-FA complex based on 5-8 ns MD 
simulations (in units of Å). 
 
 MYR PLM 
Unliganded HSA 27.63 ± 0.10 27.61 ± 0.15 
HSA-7FA 28.54 ± 0.17 28.40 ± 0.27 
HSA-1FA (Site 2) 27.59 ± 0.11 27.81 ± 0.40 
HSA-1FA (Site 4) 27.69 ± 0.12 27.67 ± 0.18 




Figure 1. Ribbon model of HSA-MYR complex, derived from X-ray crystallography (PDB 
entry 1E7G). HSA is composed of three homologous domains I–III, each of which is divided 
into two subdomains, A and B. The seven MYR molecules are shown in black in a space-
filling representation. Numbering of the sites is taken from Bhattacharya et al. (8). This 
diagram was generated using Visual Molecular Dynamics (VMD; version 1.8.5) (52). 
 
Figure 2. Time evolution of the RMSD of Cα atoms from the starting structure during 8 ns 
MD simulations of  HSA-7FA complex models (A), and 4-8 ns simulations of unliganded 
HSA models (B).  
 
Figure 3. Time evolution of the RMSD of Cα atoms belonging to each subdomain of HSA-
7FA complex model from the starting structure during 8 ns MD simulations. All Cα atoms 
were fitted to the starting structure. 
 
Figure 4. Relationship between experimental and calculated binding free energy for the three 
high affinity FA binding sites (Sites 5, 4, 2). Affinity constants (K1, K2, K3) were taken from 
references, where circle, triangle, and square symbols are corresponding to Ashbrook et al. 
(27), Pedersen et al. (28), and Richieri et al. (29). The experimental binding free energy 
(ΔGbind,expt) was calculated by lnRT K− , where R and T are the gas constant and the absolute 
temperature, respectively. 
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